Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Slides:

Advertisements

Similar presentations

THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.

Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Signal transduction. General scheme There are two general types of receptors: cell-surface and intracellular receptors.

Schema for a human microbiome study

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Inhibitor of MAP kinase activation blocks colon cancer growth

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Advances in Specific Immunotherapy for Prostate Cancer

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Victoria Sherwood, Irene M. Leigh Journal of Investigative Dermatology

Schematic diagram of antibody drug conjugate

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Cell Communication.

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Molecular approaches to HER2 targeted therapy

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

Targeted Therapies in Melanoma: Translational Research at Its Finest

ADVANCED TARGETING SYSTEMS for specific elimination of cell types

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Model of the function of TBX2 in RMS.

Volume 29, Issue 3, Pages (March 2016)

The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

Bhagelu Ram Achyut, Li Yang Gastroenterology

A genome-based strategy uncovers frequent BRAF mutations in melanoma

The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Figure 5 The mechanism underlying epithelial-to-mesenchymal

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Vascular Endothelial Growth Factor (VEGF) Pathway

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,

HDACs class I, II, IV mutations in human cancer

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Figure 1 Mechanisms of action of immunotherapy modalities

Mitochondrial priming model

Nat. Rev. Cardiol. doi: /nrcardio

Spectrum of cellular processes regulated by AXL activity

Oncogenic ALK signaling.

Figure 1 from D’Incalci et al.

Involvement of actin cytoskeletal reorganisation in EMT

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

Releasing the Brakes on Cancer Immunotherapy

Presentation transcript:

Model of the signalling pathways implicated in fusion-positive ARMS progression. Figure 1 from B Zhu British Journal of Cancer (2015) 112, 227-231; doi:10.1038/bjc.2014.513 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2015 Cancer Research UK.